MRK vs WFC: Which Is the Better Buy?

Side-by-side comparison of Merck & Co., Inc. and Wells Fargo & Company β€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-09-19.
Merck & Co., Inc. Β· Healthcare
$147.17
-4.1% upside to fair value
Med Conviction Grade C
VS
Wells Fargo & Company Β· Financial Services
$86.12
+20.4% upside to fair value
Med Conviction Grade B
QuantHub Verdict
WFC has more upside to fair value (+20.4%). These are model outputs β€” not personalized investment advice. See all research β†’
Valuation & Fundamentals
Metric MRK WFC
Current Price $147.17 $86.12
Fair Value Estimate $141.07 $103.68
Upside to Fair Value -4.1% +20.4%
Market Cap $363.5B $260.4B
Forward P/E β€” β€”
EV / EBITDA 29.6x 15.6x
Price / Sales 5.5x 2.0x
Price / FCF 22.6x 13.7x
Revenue Growth YoY +5.1% +11.3%
Gross Margin 75.4% 64.5%
Operating Margin 16.7% 21.2%
Return on Equity 6.6% 12.6%
Dividend Yield 2.31% 2.15%
FCF Yield 4.42% 7.3%
Analyst Consensus Buy Hold
Investment Thesis
MRK β€” Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with two core divisions, Pharmaceuticals and Animal Health, spanning oncology, vaccines, acute hospital care, immunology, neuroscience, virology, cardiovascular and diabetes, and it employs roughly 74,000 people under CEO Robert Davis. The business quality is medium: TTM gross margin of 75.4% and TTM operating margin of 16.7% reflect a genuinely hig…
WFC β€” Wells Fargo & Company
Wells Fargo is a diversified U.S. bank with roughly 197,000 employees operating four segments: Consumer Banking and Lending, Commercial Banking, Corporate and Investment Banking, and Wealth and Investment Management. The business quality is solid but not exceptional: trailing return on equity is 12.6%, TTM net margin is 17.5%, and revenue grew 11.3% year over year in the most recent quarter while…
Accumulation Zones
Metric MRK WFC
Zone Low $105.80 $77.76
Zone High $119.91 $88.13
In Buy Zone? No Yes
← MRK Research    WFC Research β†’    All Research